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Abstract: An international consensus document was recently published and provides guidance 
on the diagnosis, treatment and monitoring of late-onset hypogonadism (LOH) in men. The 
diagnosis of LOH requires biochemical and clinical components. Controversy in deﬁ  ning the 
clinical syndrome continues due to the high prevalence of hypogonadal symptoms in the aging 
male population and the non-speciﬁ  c nature of these symptoms. Further controversy surrounds 
setting a lower limit of normal testosterone, the limitations of the commonly available total 
testosterone result in assessing some patients and the unavailability of reliable measures of 
bioavailable or free testosterone for general clinical use. As with any clinical intervention 
testosterone treatment should be judged on a balance of risk versus beneﬁ  t. The traditional 
beneﬁ  ts of testosterone on sexual function, mood, strength and quality of life remain the primary 
goals of treatment but possible beneﬁ  cial effects on other parameters such as bone density, 
obesity, insulin resistance and angina are emerging and will be reviewed. Potential concerns 
regarding the effects of testosterone on prostate disease, aggression and polycythaemia will 
also be addressed. The options available for treatment have increased in recent years with the 
availability of a number of testosterone preparations which can reliably produce physiological 
serum concentrations.
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Introduction
The prevalence of biochemical testosterone deﬁ  ciency increases with age. This is partly 
due to decreasing testosterone levels associated with illness or debility but there is also 
convincing epidemiological data to show that serum free and total testosterone levels 
also fall with normal aging (Harman et al 2001; Feldman et al 2002). The symptoms 
of aging include tiredness, lack of energy, reduced strength, frailty, loss of libido, 
decreased sexual performance depression and mood change. Men with hypogonadism 
experience similar symptoms. This raises the question of whether some symptoms 
of aging could be due to relative androgen deﬁ  ciency. On the other hand, similarities 
between normal aging and the symptoms of mild androgen deﬁ  ciency make the clini-
cal diagnosis of hypogonadism in aging men more challenging.
Epidemiological studies suggest that many signiﬁ  cant clinical ﬁ  ndings and impor-
tant disease states are linked to low testosterone levels. These include osteoporosis 
(Campion and Maricic 2003), Alzheimer’s disease (Moffat et al 2004), frailty, obesity 
(Svartberg, von Muhlen, Sundsfjord et al 2004), diabetes (Barrett-Connor 1992), 
hypercholesterolemia (Haffner et al 1993; Van Pottelbergh et al 2003), hypertension 
(Phillips et al 1993), cardiac failure (Tappler and Katz 1979; Kontoleon et al 2003) 
and ischemic heart disease (Barrett-Connor and Khaw 1988). The extent to which 
testosterone deﬁ  ciency is involved in the pathogenesis of these conditions, or to which 
testosterone supplementation could be useful in their treatment is an area of great 
interest with many unanswered questions.Clinical Interventions in Aging 2008:3(1) 26
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This paper will aim to review the current evidence of 
clinical effects of testosterone treatment within an aging male 
population. As with any other clinical intervention a decision 
to treat patients with testosterone requires a balance of risk 
versus beneﬁ  t. We shall try to facilitate this by examining 




‘A clinical and biochemical syndrome associated with 
advancing age and characterised by typical symptoms and 
a deﬁ  ciency in serum testosterone levels. It [late-onset 
hypogonadism] may result in signiﬁ  cant detriment in the 
quality of life and adversely affect the function of multiple 
organ systems’ (Nieschlag et al 2005).
— ISA, ISSAM, and EAU recommendations.
Male hypogonadism is a clinical syndrome caused by a lack 
of androgens or their action. Causes of hypogonadism may 
reﬂ  ect abnormalities of the hypothalamus, pituitary, testes or 
target tissues. Increases in the amount of testosterone con-
verted to estrogen under the action of the enzyme aromatase 
may also contribute to hypogonadism. Most aspects of the 
clinical syndrome are unrelated to the location of the cause. 
A greater factor in the production of a clinical syndrome is 
the age of onset. The development of hypogonadism with 
aging is known as late-onset hypogonadism and is charac-
terised by loss of vitality, fatigue, loss of libido, erectile 
dysfunction, somnolence, depression and poor concentration. 
Hypogonadal ageing men also gain fat mass and lose bone 
mass, muscle mass and strength.
The diagnosis of late-onset hypogonadism requires the 
combination of low serum testosterone levels with symp-
toms of hypogonadism. Questionnaires are available which 
check for the symptoms of hypogonadism. These have been 
validated for the assessment of aging patients with hypogo-
nadism (Morley et al 2000; Moore et al 2004) but have a 
low speciﬁ  city. In view of the overlap in symptoms between 
hypogonadism, aging and other medical conditions it is wise 
to use a formal method of symptom assessment which can be 
used to monitor the effects of testosterone replacement.
In order to discuss the biochemical diagnosis of hypogo-
nadism it is necessary to outline the usual carriage of testos-
terone in the blood. Total serum testosterone consists of free 
testosterone (2%–3%), testosterone bound to sex hormone 
binding globulin (SHBG) (45%) and testosterone bound to 
other proteins (mainly albumin −50%) (Dunn et al 1981). 
Testosterone binds only loosely to albumin and so this testos-
terone as well as free testosterone is available to tissues and 
is termed bioavailable testosterone. Testosterone bound to 
SHBG is tightly bound and is biologically inactive. Bioavail-
able and free testosterone are known to correlate better than 
total testosterone with clinical sequelae of androgenization 
such as bone mineral density and muscle strength (Khosla 
et al 1998; Roy et al 2002). There is diurnal variation in serum 
testosterone levels with peak levels seen in the morning fol-
lowing sleep, which can be maintained into the seventh decade 
(Diver et al 2003). Samples should always be taken in the 
morning before 11 am to allow for standardization.
The reliable measurement of serum free testosterone 
requires equilibrium dialysis. This is not appropriate for clini-
cal use as it is very time consuming and therefore expensive. 
The amount of bioavailable testosterone can be measured as 
a percentage of the total testosterone after precipitation of the 
SHBG bound fraction using ammonium sulphate. The bioavail-
able testosterone is then calculated from the total testosterone 
level. This method has an excellent correlation with free testos-
terone (Tremblay and Dube 1974) but is not widely available 
for clinical use. In most clinical situations the available tests are 
total testosterone and SHBG which are both easily and reliably 
measured. Total testosterone is appropriate for the diagnosis 
of overt male hypogonadism where testosterone levels are 
very low and also in excluding hypogonadism in patients with 
normal/high-normal testosterone levels. With increasing age, a 
greater number of men have total testosterone levels just below 
the normal range or in the low-normal range. In these patients 
total testosterone can be an unreliable indicator of hypogonadal 
status. There are a number of formulae that calculate an esti-
mated bioavailable or free testosterone level using the SHBG 
and total testosterone levels. Some of these have been shown to 
correlate well with laboratory measures and there is evidence 
that they more reliably indicate hypogonadism than total tes-
tosterone in cases of borderline biochemical hypogonadism 
(Vermeulen et al 1971; Morris et al 2004). It is important that 
such tests are validated for use in patient populations relevant 
to the patient under consideration.
Recently, a panel with cooperation from international 
andrology and urology societies, published speciﬁ  c rec-
ommendations with regard to the diagnosis of Late-onset 
Hypogonadism (Nieschlag et al 2005). These are summa-
rized in the following text. It is advised that at least two 
serum testosterone measurements, taken before 11 am on 
different mornings, are necessary to conﬁ  rm the diagnosis. 
The second sample should also include measurement of 
gonadotrophin and prolactin levels, which may indicate the Clinical Interventions in Aging 2008:3(1) 27
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need for further investigations for pituitary disease. Patients 
with serum total testosterone consistently below 8 nmol/l 
invariably demonstrate the clinical syndrome of hypogo-
nadism and are likely to beneﬁ  t from treatment. Patients 
with serum total testosterone in the range 8–12 nmol/l often 
have symptoms attributable to hypogonadism and it may be 
decided to offer either a clinical trial of testosterone treat-
ment or to make further efforts to deﬁ  ne serum bioavailable 
or free testosterone and then reconsider treatment. Patients 
with serum total testosterone persistently above 12 nmol/l 
do not have hypogonadism and symptoms are likely to be 
due to other disease states or ageing per se so testosterone 
treatment is not indicated.
Changes in testosterone levels 
with aging
Longitudinal studies in male aging studies have shown that 
serum testosterone levels decline with age (Harman et al 
2001; Feldman et al 2002). Total testosterone levels fall at 
an average of 1.6% per year whilst free and bioavailable 
levels fall by 2%–3% per year. The reduction in free and 
bioavailable testosterone levels is larger because aging is 
also associated with increases in SHBG levels (Feldman 
et al 2002). Cross-sectional data supports these trends but 
has usually shown smaller reductions in testosterone levels 
with aging (Feldman et al 2002). This is likely to reﬂ  ect strict 
entry criteria to cross-sectional studies so that young healthy 
men are compared to older healthy men. During the course 
of longitudinal studies some men may develop pathologies 
which accentuate decreases in testosterone levels.
The changes in average serum testosterone levels with 
aging mean that the proportion of men fulﬁ  lling a bio-
chemically deﬁ  ned diagnosis of hypogonadism increases 
with aging. Twenty percent of men aged over 60 have total 
testosterone levels below the normal range and the ﬁ  gure 
rises to 50% in those aged over 80. The ﬁ  gures concerning 
free testosterone are even higher as would be expected in 
view of the concurrent decrease in SHBG levels (Harman 
et al 2001).
The mechanism of age related decreases in serum tes-
tosterone levels has also been the subject of investigation. 
Metabolic clearance declines with age but this effect is less 
pronounced than a reduction in testosterone production, 
so the overall effect is to reduce serum testosterone levels. 
Gonadotrophin levels rise during aging (Feldman et al 2002) 
and testicular secretory responses to recombinant human 
chorionic gonadotrophin (hCG) are reduced (Mulligan et al 
1999, 2001). This implies that the reduced production may be 
caused by primary testicular failure but in fact these changes 
are not adequate to fully explain the fall in testosterone levels. 
There are changes in the lutenising hormone (LH) produc-
tion which consist of decreased LH pulse frequency and 
amplitude, (Veldhuis et al 1992; Pincus et al 1997) although 
pituitary production of LH in response to pharmacological 
stimulation with exogenous GnRH analogues is preserved 
(Mulligan et al 1999). It therefore seems likely that there are 
changes in endogenous production of GnRH which underlie 
the changes in LH secretion and have a role in the age related 
decline in testosterone. Thus the decreases in testosterone 
levels with aging seem to reﬂ  ect changes at all levels of the 
hypothalamic-pituitary-testicular axis. With advancing age 
there is also a reduction in androgen receptor concentration 
in some target tissues and this may contribute to the clinical 
syndrome of LOH (Ono et al 1988; Gallon et al 1989).
Interpretation of clinical trials 
of testosterone treatment
Before assessing the evidence of testosterone’s action in the 
aging male it is important to note certain methodological 
considerations which are common to the interpretation of 
any clinical trial of testosterone replacement. Many inter-
ventional trials of the effects of testosterone on human health 
and disease have been conducted. There is considerable 
heterogenicity in terms of study design and these differences 
have a potential to signiﬁ  cantly affect the results seen in 
various studies. Gonadal status at baseline and the testos-
terone level produced by testosterone treatment in the study 
are of particular importance because the effects of altering 
testosterone from subphysiological to physiological levels 
may be different from those of altering physiological levels 
to supraphysiological. Another important factor is the length 
of treatment. Randomised controlled trials of testosterone 
have ranged from one to thirty-six months in duration (Isidori 
et al 2005) although some uncontrolled studies have lasted 
up to 42 months. Many effects of testosterone are thought to 
fully develop in the ﬁ  rst few months of treatment but effects 
on bone, for example, have been shown to continue over 
two years or more (Snyder et al 2000; Wang, Cunningham 
et al 2004).
Late onset hypogonadism reﬂ  ects a particular patho-
physiology and it may not be appropriate to extrapolate 
results from studies concerning the effects of testoster-
one in treating hypogonadism of other etiology to aging 
males. For this reason, the age of men treated in clinical 
trials is certainly relevant. Other important factors include 
patient comorbidities and the preparation and route of Clinical Interventions in Aging 2008:3(1) 28
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testosterone replacement used in the study, which can 
affect the production of estrogen and dihydrotestosterone, 
testosterone’s active metabolites
Effects on bone and osteoporosis
Osteoporosis refers to pathological loss of bone density and 
strength. It is an important condition due to its prevalence 
and association with bone fractures; most commonly of 
the hip, vertebra and forearm. Men are relatively protected 
from the development of osteoporosis by a higher peak 
bone mass compared with women (Campion and Maricic 
2003). Furthermore, women lose bone at an accelerated 
rate immediately following the menopause. Neverthe-
less, men start to lose bone mass during early adult life 
and experience an increase in the rate of bone loss with 
age (Scopacasa et al 2002). Women of a given age have 
a higher prevalence of osteoporosis in comparison to 
men but the prevalence increases with age in both sexes. 
As a result, men have a lower incidence of osteoporotic 
fractures than women of a given age but the gap between 
the sexes narrows with advancing age (Chang et al 2004) 
and there is evidence that hip fractures in men are associ-
ated with greater mortality than in women (Campion and 
Maricic 2003).
A number of epidemiological studies have found that 
bone mineral density in the aging male population is 
positively associated with endogenous androgen levels 
(Murphy et al 1993; Ongphiphadhanakul et al 1995; Rucker 
et al 2004). Testosterone levels in young men have been 
shown to correlate with bone size, indicating a role in 
determination of peak bone mass and protection from future 
osteoporosis (Lorentzon et al 2005). Male hypogonadism 
has been shown to be a risk factor for hip fracture (Jackson 
et al 1992) and a recent study showed a high prevalence of 
hypogonadism in a group of male patients with average age 
75 years presenting with minimal trauma fractures compared 
to stroke victims who acted as controls (Leifke et al 2005). 
Estrogen is a well known determinant of bone density in 
women and some investigators have found serum estrogen 
to be a strong determinant of male bone density (Khosla et al 
1998; Khosla et al 2001). Serum estrogen was also found 
to correlate better than testosterone with peak bone mass 
(Khosla et al 2001) but this is in contradiction of a more 
recent study showing a negative correlation of estrogen with 
peak bone size (Lorentzon et al 2005). Men with aromatase 
deﬁ  ciency (Carani et al 1997) or defunctioning estrogen 
receptor mutations (Smith et al 1994) have been found to 
have abnormally low bone density despite normal or high 
testosterone levels which further emphasizes the important 
inﬂ  uence of estrogen on male bone density.
A large number of trials have demonstrated a positive 
effect of testosterone treatment on bone mineral density 
(Katznelson et al 1996; Behre et al 1997; Leifke et al 1998; 
Snyder et al 2000; Zacharin et al 2003; Wang, Cunningham 
et al 2004; Aminorroaya et al 2005; Benito et al 2005) and 
bone architecture (Benito et al 2005). These effects are often 
more impressive in longer trials, which have shown that 
adequate replacement will lead to near normal bone density 
but that the full effects may take two years or more (Snyder 
et al 2000; Wang, Cunningham et al 2004; Aminorroaya 
et al 2005). Three randomized placebo-controlled trials of 
testosterone treatment in aging males have been conducted 
(Snyder et al 1999; Kenny et al 2001; Amory et al 2004). 
One of these studies concerned men with a mean age of 71 
years with two serum testosterone levels less than 12.1nmol/l. 
After 36 months of intramuscular testosterone treatment or 
placebo, there were signiﬁ  cant increases in vertebral and 
hip bone mineral density. In this study, there was also a 
signiﬁ  cant decrease in the bone resorption marker urinary 
deoxypyridinoline with testosterone treatment (Amory et al 
2004). The second study contained men with low bioavail-
able testosterone levels and an average age of 76 years. 
Testosterone treatment in the form of transdermal patches 
was given for 1 year. During this trial there was a signiﬁ  cant 
preservation of hip bone mineral density with testosterone 
treatment but testosterone had no effect on bone mineral 
density at other sites including the vertebrae. There were no 
signiﬁ  cant alterations in bone turnover markers during tes-
tosterone treatment (Kenny et al 2001). The remaining study 
contained men of average age 73 years. Men were eligible 
for the study if their serum total testosterone levels were less 
than 16.5 nmol/L, meaning that the study contained men 
who would usually be considered eugonadal. The beneﬁ  cial 
effects of testosterone on bone density were conﬁ  ned to the 
men who had lower serum testosterone levels at baseline and 
were seen only in the vertebrae. There were no signiﬁ  cant 
changes in bone turnover markers. Testosterone in the trial 
was given via scrotal patches for a 36 month duration (Snyder 
et al 1999). A recent meta-analysis of the effects on bone 
density of testosterone treatment in men included data from 
these studies and two other randomized controlled trials. 
The ﬁ  ndings were that testosterone produces a signiﬁ  cant 
increase of 2.7% in the bone mineral density at the lumber 
spine but no overall change at the hip (Isidori et al 2005). 
These results from randomized controlled trials in aging men 
show much smaller beneﬁ  ts of testosterone treatment on bone Clinical Interventions in Aging 2008:3(1) 29
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density than have been seen in other trials. This could be due 
to the trials including patients who are not hypogonadal and 
being too short to allow for the maximal effects of testos-
terone. The meta-analysis also assessed the data concerning 
changes of bone formation and resorption markers during 
testosterone treatment. There was a signiﬁ  cant decrease in 
bone resorption markers but no change in markers of bone 
formation suggesting that reduction of bone resorption may 
be the primary mode of action of testosterone in improving 
bone density (Isidori et al 2005).
Overall, it seems that both estrogen and testosterone are 
important for normal bone growth and maintenance. Deﬁ  -
ciency or failure of action of the sex hormones is associated 
with osteoporosis and minimal trauma fractures. Estrogen 
in males is produced via metabolism of testosterone by aro-
matase and it is therefore important that androgens used for 
the treatment of hypogonadism be amenable to the action of 
aromatase to yield maximal positive effects on bone. There is 
data showing that testosterone treatment increases bone min-
eral density in aging males but that these beneﬁ  ts are conﬁ  ned 
to hypogonadal men. The magnitude of this improvement is 
greater in the spine than in the hip and further studies are 
warranted to conﬁ  rm or refute any differential effects of 
testosterone at these important sites. Improvements seen 
in randomized controlled trials to date may underestimate 
true positive effects due to relatively short duration and/or 
baseline characteristics of the patients involved. There is no 
data as yet to conﬁ  rm that the improvement in bone density 
with testosterone treatment reduces fractures in men and this 
is an important area for future study.
Testosterone and body composition
Changes in body composition are seen with aging. In general 
terms, aging males are prone to loss of muscle mass and a 
gain in fat mass, especially in the form of visceral or central 
fat. An epidemiological study of community dwelling men 
aged between 24 and 85 years has conﬁ  rmed that total and 
free testosterone levels are inversely correlated with waist 
circumference and that testosterone levels are speciﬁ  cally 
related to this measure of central obesity rather than general 
obesity (Svartberg, von Muhlen, Sundsfjord et al 2004). Pro-
spective studies show that testosterone levels predict future 
development of central obesity (Khaw and Barrett-Connor 
1992; Tsai et al 2000). Reductions in free testosterone also 
correlate with age related declines in fat free mass (muscle 
mass) and muscle strength (Baumgartner et al 1999; Roy 
et al 2002). Studies in hypogonadal men conﬁ  rm an increase 
in fat mass and decrease in fat free mass versus comparable 
eugonadal men (Katznelson et al 1998). Taken together, 
the epidemiological data suggest that a hypogonadal state 
promotes loss of muscle mass and a gain in fat mass, par-
ticularly visceral fat and therefore mimics the changes of 
‘normal’ aging.
A number of research groups have tried to further deﬁ  ne 
the relationship of testosterone and body composition 
by artiﬁ  cial alteration of testosterone levels in eugonadal 
populations. Induction of a hypogonadal state in healthy men 
(Mauras et al 1998) or men with prostate cancer (Smith et al 
2001) using a gonadotrophin-releasing-hormone (GnRH) 
analogue was shown to produce increases in fat mass and 
decreased fat free mass. Another experimental approach in 
healthy men featured suppression of endogenous testosterone 
production with a GnRH analogue, followed by treatment 
with different doses of weekly intramuscular testosterone 
esters for 20 weeks. Initially the experiments involved men 
aged 18–35 years (Bhasin et al 2001) but subsequently the 
study was repeated with a similar protocol in men aged 
60–75 years (Bhasin et al 2005). The different doses given 
were shown to produce a range of serum concentrations from 
subphysiological to supraphysiological (Bhasin et al 2001). 
A given testosterone dose produced higher serum concen-
trations of testosterone in the older age group (Bhasin et al 
2005). Subphysiological dosing of testosterone produced a 
gain in fat mass and loss of fat free mass during the study. 
There were sequential decreases in fat mass and increases in 
fat free mass with each increase of testosterone dose. These 
changes in body composition were seen in physiological and 
supraphysiological treatment doses. The trend was similar 
in younger versus older men but the gain of fat mass at the 
lowest testosterone dose was less prominent in older patients 
(Bhasin et al 2001; Bhasin et al 2005). With regard to muscle 
function, the investigators showed dose dependent increases 
in leg strength and power with testosterone treatment in 
young and older men but there was no improvement in fati-
gability (Storer et al 2003; Bhasin et al 2005).
Many clinical studies have looked at the effect of tes-
tosterone treatment on body composition in hypogonadal 
men or men with borderline low testosterone levels. Some 
of these studies specifically examine these changes in 
older men (Tenover 1992; Morley et al 1993; Urban et al 
1995; Sih et al 1997; Snyder et al 1999; Kenny et al 2001; 
Ferrando et al 2002; Steidle et al 2003; Page et al 2005). 
The data from studies, on patients from all age groups, 
are consistent in showing an increase in fat free mass and 
decrease in fat mass or visceral adiposity with testoster-
one treatment. A recent meta-analysis of 16 randomized Clinical Interventions in Aging 2008:3(1) 30
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controlled trials of testosterone treatment effects on body 
composition conﬁ  rms this pattern (Isidori et al 2005). There 
have been less consistent results with regard to the effects 
of testosterone treatment of muscle strength. Some studies 
have shown an increase in muscle strength (Ferrando et al 
2002; Page et al 2005) with testosterone whilst others have 
not (Snyder et al 1999). Within the same trial some muscle 
group strengths may improve whilst others do not (Ly et al 
2001). It is likely that the differences are partly due to 
the methodological variations in assessing strength, but it 
also possible that testosterone has different effects on the 
various muscle groups. The meta-analysis found trends 
toward signiﬁ  cant improvements in dominant knee and hand 
grip strength only (Isidori et al 2005).
Overall there is evidence that testosterone treatment 
increases lean body mass and reduces obesity, particularly 
visceral obesity, in a variety of populations including aging 
men. With regard to muscle changes, some studies dem-
onstrate improvements in maximal strength but the results 
are inconsistent and it has not been demonstrated that these 
changes lead to clinically important improvements in mobil-
ity, endurance or quality of life. Studies are needed to clarify 
this. Changes in abdominal obesity are particularly important 
as visceral fat is now recognised as predisposing the meta-
bolic syndrome, diabetes and cardiovascular disease.
Testosterone, diabetes 
and the metabolic syndrome
Type 2 diabetes is an important condition in terms of mor-
bidity and mortality, and the prevalence is increasing in 
the developed and developing world. The prevalence also 
increases with age. Insulin resistance is a primary pathologi-
cal feature of type 2 diabetes and predates the onset of dia-
betes by many years, during which time raised serum insulin 
levels compensate and maintain normoglycemia. Insulin 
resistance and/or impaired glucose tolerance are also part of 
the metabolic syndrome which also comprises an abnormal 
serum lipid proﬁ  le, central obesity and hypertension. The 
metabolic syndrome can be considered to be a pre-diabetic 
condition and is itself linked to cardiovascular mortality. 
Table 1 shows the three commonly used deﬁ  nitions of the 
metabolic syndrome as per WHO, NCEPIII and IDF respec-
tively (WHO 1999; NCEPIII 2001; Zimmet et al 2005).
Epidemiological evidence supports a link between 
testosterone and glucose metabolism. Studies in non-diabetic 
men have found an inverse correlation of total or free testosterone 
with glucose and insulin levels (Simon et al 1992; Haffner et al 
1994) and studies show lower testosterone levels in patients 
with the metabolic syndrome (Laaksonen et al 2003; Muller 
et al 2005; Kupelian et al 2006) or diabetes (Barrett-Connor 
1992; Andersson et al 1994; Rhoden et al 2005). A study of 
patients with type 2 diabetes using measurement of serum 
free testosterone by the gold standard method of equilibrium 
dialysis, found a 33% prevalence of biochemical hypogonadism 
(Dhindsa et al 2004). The Barnsley study demonstrated a 
high prevalence of clinical and biochemical hypogonadism 
with 19% having total testosterone levels below 8 nmol/l and 
a further 25% between 8–12 nmol/l (Kapoor, Aldred et al 
2007). There are also a number longitudinal studies linking 
low serum testosterone levels to the future development of the 
metabolic syndrome (Laaksonen et al 2004) or type 2 diabetes 
(Haffner et al 1996; Tibblin et al 1996; Stellato et al 2000; Oh 
et al 2002; Laaksonen et al 2004), indicating a possible role 
of hypogonadism in the pathogenesis of type 2 diabetes in 
men. Alternatively, it has been postulated that obesity may be 
the common link between low testosterone levels and insulin 
resistance, diabetes and cardiovascular disease (Phillips et al 
2003; Kapoor et al 2005). With regard to this hypothesis, study 
ﬁ  ndings vary as to whether the association of testosterone with 
diabetes occurs independently of obesity (Haffner et al 1996; 
Laaksonen et al 2003; Rhoden et al 2005).
Clinical trials of the effect of testosterone on glucose 
metabolism in men have occurred in diabetic and non-diabetic 
populations. Data speciﬁ  c to aging males is not available. A 
series of studies investigated the effects of testosterone or 
dihydrotestosterone given for 6 weeks or 3 months to middle 
aged, non-diabetic obese men (Marin, Holmang et al 1992; 
Marin, Krotkiewski et al 1992; Marin et al 1993). It was 
found that physiological treatment doses led to improved 
insulin resistance, as measured by the gold standard technique 
using a euglycemic clamp and/or serum glucose and insulin 
responses during glucose tolerance test. These improvements 
were associated with decreased central obesity, measured 
by computered tomography (CT) or waist-hip ratio, without 
reduced total fat mass. Insulin resistance improved more with 
testosterone than dihydrotestosterone treatment and beneﬁ  cial 
effects were greater in men with lower baseline testosterone 
levels. Increasing testosterone levels into the supraphysiologi-
cal range lead to decreased glucose tolerance.
Trials of testosterone treatment in men with type 2 diabetes 
have also taken place. A recent randomized controlled cross-
over trial assessed the effects of intramuscular testosterone 
replacement to achieve levels within the physiological range, 
compared with placebo injections in 24 men with diabetes, 
hypogonadism and a mean age of 64 years (Kapoor et al 2006). 
Ten of these men were insulin treated. Testosterone treatment Clinical Interventions in Aging 2008:3(1) 31
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led to a signiﬁ  cant reduction in glycated hemoglobin (HbA1C) 
and fasting glucose compared to placebo. Testosterone also 
produced a signiﬁ  cant reduction in insulin resistance, measured 
by the homeostatic model assessment (HOMA), in the fourteen 
non-insulin treated patients. It is not possible to measure insulin 
resistance in patients treated with insulin but ﬁ  ve out of ten of 
these patients had a reduction of insulin dose during the study. 
Other signiﬁ  cant changes during testosterone treatment in this 
trial were reduced total cholesterol, waist circumference and 
waist-hip ratio. Similarly, a placebo-controlled but non-blinded 
trial in 24 men with visceral obesity, diabetes, hypogonadism 
and mean age 57 years found that three months of oral testos-
terone treatment led to signiﬁ  cant reductions in HbA1C, fasting 
glucose, post-prandial glucose, weight, fat mass and waist-hip 
ratio (Boyanov et al 2003). In contrast, an uncontrolled study 
of 150 mg intramuscular testosterone given to 10 patients, 
average age 64 years, with diabetes and hypogonadism found 
no signiﬁ  cant change in diabetes control, fasting glucose or 
insulin levels (Corrales et al 2004). Another uncontrolled 
study showed no beneﬁ  cial effect of testosterone treatment on 
insulin resistance, measured by HOMA and ‘minimal model’ 
of area under acute insulin response curves, in 11 patients 
with type 2 diabetes aged between 33 and 73 years (Lee et al 
2005). Body mass index was within the normal range in this 
population and there was no change in waist-hip ratio or 
weight during testosterone treatment. Baseline testosterone 
levels were in the low-normal range and patients received a
 relatively small dose of 100 mg intramuscular testosterone 
every three weeks. A good increase in testosterone levels 
during the trial is described but it is not stated at which time 
during the three week cycle the testosterone levels were tested, 
so the lack of response could reﬂ  ect an insufﬁ  cient overall 
testosterone dose in the trial period.
Findings that improvements in serum glucose, serum 
insulin, insulin resistance or glycemic control, in men treated 
with testosterone are accompanied by reduced measures 
of central obesity, are in line with other studies showing a 
speciﬁ  c effect of testosterone in reducing central or visceral 
obesity (Rebuffe-Scrive et al 1991; Marin, Holmang et al 
1992). Furthermore, studies that have shown neutral effects 
of testosterone on glucose metabolism have not measured 
(Corrales et al 2004), or shown neutral effects (Lee et al 
2005) (Tripathy et al 1998; Bhasin et al 2005) on central 
obesity. Given the known association of visceral obesity 
with insulin resistance, it is possible that testosterone treat-
ment of hypogonadal men acts to improve insulin resistance 
and diabetes through an effect in reducing central obesity. 
This effect can be explained by the action of testosterone in 
inhibiting lipoprotein lipase and thereby reducing triglyc-
eride uptake into adipocytes (Sorva et al 1988), an action 
which seems to occur preferentially in visceral fat (Marin 
et al 1995; Marin et al 1996). Visceral fat is thought to be 
more responsive to hormonal changes due to a greater con-
centration of androgen receptors and increased vascularity 
compared with subcutaneous fat (Bjorntorp 1996). Further 
explanation of the links between hypogonadism and obesity 
is offered by the hypogonadal-obesity-adipocytokine cycle 
hypothesis (see Figure 1). In this model, increases in body 
fat lead to increases in aromatase levels, in addition to insulin 
resistance, adverse lipid proﬁ  les and increased leptin levels. 
Increased action of aromatase in metabolizing testosterone 
to estrogen, reduces testosterone levels which induces 
further accumulation of visceral fat. Higher leptin levels 
and possibly other factors, act at the pituitary to suppress 
gonadotrophin release and exacerbate hypogonadism (Cohen 
1999; Kapoor et al 2005). Leptin has also been shown to 
Table 1 Deﬁ  nition of the metabolic syndrome
   WHO  IDF  NCEP III
Essential  Diabetes, impaired glucose tolerance  Central obesity (men 94 cm waist,   No essential feature
feature  or insulin resistancea women  80 cm waist)   
   Essential feature plus 2 from;  Essential feature plus 2 from;  Diagnosis requires three factors from;
Diagnosis Hypertension  (140/90) Hypertension  (130/85) Hypertension  (130/85)
requires Hypertriglyceridaemia  (1.7 mmol/l)  Hypertriglyceridaemia (1.7 mmol/l)  Hypertriglyceridaemia (1.7 mmol/l)
   Low HDL cholesterolb  Low HDL cholesterol (1.03 mmol/l)  Low HDL cholesterol (1.03 mmol/l)
   Central obesityc  Raised fasting glucose (5.6 mmol/l)  Raised fasting glucose (5.6 mmol/l)
   Microalbuminuriad     Central obesitye
aImpaired glucose tolerance = glucose 7.8 mmol on 2 hour glucose tolerance test. Insulin resistance = in highest quartile of relevant population.
bHDL cholesterol <0.9 mmol/l in men, 1.0 mmol/l in women.
cWaist-hip ratio 0.9 in men, 0.85 in women or BMI greater than 30.
dalbumin-creatinine ratio 30.
eWaist circumference 102 cm in men, 88 cm in women.
Abbreviations: WHO,  World Health Organisation deﬁ  nition of the metabolic syndrome; IDF, International Diabetes Federation deﬁ  nition of the metabolic syndrome; 
NCEP, National Cholesterol Education Program Expert Panel III deﬁ  nition of the metabolic syndrome.Clinical Interventions in Aging 2008:3(1) 32
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reduce testosterone secretion from rodent testes in vitro 
(Tena-Sempere et al 1999). A full review of the relationship 
between testosterone, insulin resistance and diabetes can be 
found elsewhere (Kapoor et al 2005; Jones 2007).
Testosterone, cardiovascular 
disease, and atherosclerosis
Cardiovascular disease, and its underlying pathological pro-
cess atherosclerosis, is an important cause of morbidity and 
mortality in the developed and developing world. Coronary 
heart disease in particular is the commonest cause of death 
worldwide (AHA 2002; MacKay and Mensah 2004). As 
well as increasing with age, this disease is more common 
in the male versus female population internationally, which 
has led to interest in the potential role of sex hormones in 
modulating risk of development of atherosclerosis. Concerns 
about the potential adverse effects of testosterone treatment 
on cardiovascular disease have previously contributed to 
caution in prescribing testosterone to those who have, or 
who are at risk of, cardiovascular disease. Contrary to fears 
of the potential adverse effects of testosterone on cardiovas-
cular disease, there are over forty epidemiological studies 
which have examined the relationship of testosterone levels 
to the presence or development of coronary heart disease, 
and none have shown a positive correlation. Many of these 
studies have found the presence of coronary heart disease to 
be associated with low testosterone levels (Reviews: Jones, 
Jones et al 2003; Jones et al 2005).
Epidemiological studies have also assessed links between 
serum testosterone and non-coronary atherosclerosis. A study 
of over 1000 people aged 55 years and over found an inverse 
correlation between serum total and bioavailable testosterone 
and the amount of aortic atherosclerosis in men, as assessed 
by radiological methods (Hak et al 2002). Increased intima-
media thickness (IMT) is an early sign of atherosclerosis 
and has also been shown to predict cardiovascular mortality 
(Murakami et al 2005). Cross-sectional studies have found 
that testosterone levels are negatively correlated with carotid 
IMT in independently living men aged 74–93 years (van den 
Beld et al 2003), diabetic men (Fukui et al 2003) and young 
obese men (De Pergola et al 2003). A 4-year follow up study 
of the latter population showed that free testosterone was 
also inversely correlated with the rate of increase of IMT 
(Muller et al 2004).
Figure 1 The hypogonadal-obesity-adipocytokine cycle hypothesis. Adipose tissue contains the enzyme aromatase which metabolises testosterone to oestrogen.   This results 
in reduced testosterone levels, which increase the action of lipoprotein lipase and increase fat mass, thus increasing aromatisation of testosterone and completing the cycle. 
Visceral fat also promotes lower testosterone levels by reducing pituitary LH pulse amplitude via leptin and/or other factors. In vitro studies have shown that leptin also inhibits 
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This evidence, together with the beneﬁ  cial effects of 
testosterone replacement on central obesity and diabetes, 
raises the question whether testosterone treatment could be 
beneﬁ  cial in preventing or treating atherosclerosis. No trial 
of sufﬁ  cient size or duration has investigated the effect of 
testosterone replacement in primary or secondary preven-
tion cardiovascular disease. The absence of such data leads 
us to examine the relationship of testosterone to other car-
diovascular risk factors, such as adverse lipid parameters, 
blood pressure, endothelial dysfunction, coagulation factors, 
inﬂ  ammatory markers and cytokines. This analysis can sup-
ply evidence of the likely effects of testosterone on overall 
cardiovascular risk. This has limitations, however, includ-
ing the potential for diverging effects of testosterone on the 
various factors involved and the resultant impossibility of 
accurately predicting the relative impact of such changes.
Epidemiological data has associated low testosterone lev-
els with atherogenic lipid parameters, including lower HDL 
cholesterol (Lichtenstein et al 1987; Haffner et al 1993; Van 
Pottelbergh et al 2003) and higher total cholesterol (Haffner 
et al 1993; Van Pottelbergh et al 2003), LDL cholesterol 
(Haffner et al 1993) and triglyceride levels (Lichtenstein 
et al 1987; Haffner et al 1993). Furthermore, these relation-
ships are independent of other factors such as age, obesity 
and glucose levels (Haffner et al 1993; Van Pottelbergh et al 
2003). Interventional trails of testosterone replacement have 
shown that treatment causes a decrease in total cholesterol. 
A recent meta-analysis of 17 randomized controlled trials 
conﬁ  rmed this and found that the magnitude of changes was 
larger in trials of patients with lower baseline testosterone 
levels (Isidori et al 2005). The same meta-analysis found no 
signiﬁ  cant overall change in LDL or HDL cholesterol levels 
but in trials with baseline testosterone levels greater than 
10 nmol/l, there was a small reduction in HDL cholesterol 
with testosterone treatment.
Studies also show a consistent negative correlation of 
testosterone with blood pressure (Barrett-Connor and Khaw 
1988; Khaw and Barrett-Connor 1988; Svartberg, von 
Muhlen, Schirmer et al 2004). Data speciﬁ  c to the ageing 
male population suggests that this relationship is particu-
larly powerful for systolic hypertension (Fogari et al 2005). 
Interventional trials have not found a signiﬁ  cant effect of 
testosterone replacement on blood pressure (Kapoor et al 
2006).
There is a negative correlation of testosterone levels 
with plasminogen activator inhibitor-1 (PAI-1) (Glueck 
et al 1993; Phillips 1993), which is a major prothrombotic 
factor and known to be associated with progression of 
atherosclerosis, as well as other prothrombotic factors 
ﬁ  brinogen, α2-antiplasmin and factor VII (Bonithon-Kopp 
et al 1988; Glueck et al 1993; Phillips 1993; De Pergola et al 
1997). There is a positive correlation with tissue plasminogen 
activator (tPA) which is one of the major ﬁ  brinolytic agents 
(Glueck et al 1993). Interventional trials have shown a neutral 
effect of physiological testosterone replacement on the major 
clotting factors (Smith et al 2005) but supraphysiological 
androgen administration can produce a temporary mild 
pro-coagulant effect (Anderson et al 1995).
A recent study compared total and bioavailable testoster-
one levels with inﬂ  ammatory cytokines in men aged 65 and 
over. There was an inverse correlation with the pro-inﬂ  am-
matory soluble interleukin-6 receptor, but no association 
with interleukin-6 (IL-6), highly sensitive CRP (hsCRP), 
tumor necrosis factor-α (TNF-α) or interleukin-1β (IL-1β 
(Maggio et al 2006). Another trial found that young men with 
idiopathic hypogonadotrophic hypogonadism had higher 
levels of proinﬂ  ammatory factors interleukin-2 (IL-2), inter-
leukin-4 (IL-4), complement C3c and total immunoglobulin 
in comparison to controls (Yesilova et al 2000). Testosterone 
treatment in a group of hypogonadal men, mostly with known 
coronary artery disease, induced anti-inﬂ  ammatory changes 
in the cytokine proﬁ  le of reduced IL-1β and TNF-α and 
increased IL-10 (Malkin, Pugh, Jones et al 2004).
A related issue is the potential use of testosterone as a 
coronary vasodilator and anti-anginal agent. Testosterone 
has been shown to act as a vasodilator of coronary arter-
ies at physiological concentrations during angiography 
(Webb, McNeill et al 1999). Furthermore men given a 
testosterone injection prior to exercise testing showed 
improved performance, as assessed by ST changes com-
pared to placebo (Rosano et al 1999; Webb, Adamson 
et al 1999). Administration of one to three months of 
testosterone treatment has also been shown to improve 
symptoms of angina and exercise test performance (Wu and 
Weng 1993; English et al 2000; Malkin, Pugh, Morris et al 
2004). Longer term studies are underway. It is thought that 
testosterone improves angina due its vasodilatory action, 
which occurs independently of the androgen receptor, via 
blockade of L-type calcium channels at the cell membrane 
of the vascular smooth muscle in an action similar to the 
dihydropyridine calcium-channel blockers such as nifedip-
ine (Hall et al 2006).
In summary, low testosterone levels are linked to the pres-
ence of numerous cardiovascular risk factors. Testosterone 
treatment acts to improve some of these factors, but effects 
may vary according to pre- and post-treatment testosterone Clinical Interventions in Aging 2008:3(1) 34
Stanworth and Jones
levels, as well as other factors. There is little data from trials 
speciﬁ  c to aging males. Appropriately-powered randomized 
controlled trials, with cardiovascular disease primary end-
points, are needed to clarify the situation, but in the meantime 
the balance of evidence is that testosterone has either neutral 
or beneﬁ  cial effects on the risk of cardiovascular disease 
in men. It is particularly important to deﬁ  ne the effect of 
testosterone treatment on cardiovascular disease in view of 
its potential use as an anti-anginal agent.
Testosterone and cardiac failure
Studies have demonstrated reduced testosterone levels in 
men with heart failure as well as other endocrine changes 
(Tappler and Katz 1979; Kontoleon et al 2003). Treatment of 
cardiac failure with chronic mechanical circulatory support 
normalizes many of these changes, including testosterone 
levels (Noirhomme et al 1999). More recently, two double-
blind randomized controlled trials of testosterone treatment 
for men with low or low-normal serum testosterone levels and 
heart failure have shown improvements in exercise capacity 
and symptoms (Pugh et al 2004; Malkin et al 2006). The 
mechanism of these beneﬁ  ts is currently unclear, although 
a study of the acute effects of buccal testosterone given to 
men with chronic cardiac failure under invasive monitoring 
showed that testosterone increased cardiac index and reduced 
systemic vascular resistance (Pugh et al 2003). Testosterone 
may prove useful in the management of cardiac failure but 
further research is needed.
Testosterone and the prostate
The normal development of the prostate gland is dependent 
on the action of testosterone via the androgen receptor, 
and abnormal biosynthesis of the hormone or inactivating 
mutations of the androgen receptor are associated with 
a rudimentary prostate gland. Testosterone also requires 
conversion to dihydrotestosterone in the prostate gland for 
full activity. In view of this link between testosterone and 
prostate development, it is important to consider the impact 
that testosterone replacement may have on the prevalence 
and morbidity associated with benign prostatic hypertrophy 
(BPH) and prostate cancer, which are the common conditions 
related to pathological growth of the prostate gland.
Cross-sectional studies conducted at the time of 
diagnosis of BPH have failed to show consistent differences 
in testosterone levels between patients and controls. A 
prospective study also failed to demonstrate a correlation 
between testosterone and the development of BPH (Gann et al 
1995). Clinical trials have shown that testosterone treatment 
of hypogonadal men does cause growth of the prostate, but 
only to the size seen in normal men, and also causes a small 
increase in prostate speciﬁ  c antigen (PSA) within the normal 
range (Rhoden and Morgentaler 2005). Despite growth of the 
prostate a number of studies have failed to detect any adverse 
effects on symptoms of urinary obstruction or physiological 
measurements such as flow rates and residual volumes 
(Snyder et al 1999; Kenny et al 2000, 2001). Despite the 
lack of evidence linking symptoms of BPH to testosterone 
treatment, it remains important to monitor for any new 
or deteriorating problems when commencing patients on 
testosterone treatment, as the small growth of prostate tissue 
may adversely affect a certain subset of individuals.
Autopsy studies have found histological prostate cancer 
to be very common, with one series showing a prevalence 
of greater than ﬁ  fty percent in men over age sixty (Holund 
1980). The majority of histological cancers go undetected so 
that the clinical incidence of the disease is much lower, but 
it is still the most prevalent non-skin cancer in men (Jemal 
et al 2003). Prostate cancer is also unusual in comparison 
to other adult cancers in that the majority of those with the 
disease will die of other causes. Treatment of prostate cancer 
with androgen deprivation is known to be successful and is 
widely practiced, indicating an important role for testosterone 
in modifying the behavior of prostate cancer. In view of this, 
testosterone treatment is absolutely contraindicated in any 
case of known or suspected prostate cancer. The question 
of whether testosterone treatment could cause new cases of 
prostate cancer, or more likely cause progression of undiag-
nosed histological prostate cancer that would otherwise have 
remained occult, is an important consideration when treating 
ageing males with testosterone.
Cross-sectional studies have not shown raised testosterone 
levels at the time of diagnosis of prostate cancer, and in fact, 
low testosterone at the time of diagnosis has been linked with 
more locally aggressive and malignant tumors (Massengill 
et al 2003; Imamoto et al 2005; Isom-Batz et al 2005). This 
may reﬂ  ect loss of hormone related control of the tumor or the 
effect of a more aggressive tumor in decreasing testosterone 
levels. One study found that 14% of hypogonadal men, 
with normal digital rectal examination and PSA levels, had 
histological prostate cancer on biopsy. It is possible that low 
androgen levels masked the usual evidence of prostate cancer 
in this population (Morgentaler et al 1996). Most longitudinal 
studies have not shown a correlation between testosterone 
levels and the future development of prostate cancer (Carter 
et al 1995; Heikkila et al 1999; Stattin et al 2004) but a recent 
study did ﬁ  nd a positive association (Parsons et al 2005). Clinical Interventions in Aging 2008:3(1) 35
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Interpretation of such data requires care, as the presentation 
of prostate cancer could be altered or delayed in patients with 
lower testosterone levels.
There is a polymorphic CAG repeat sequence in the 
androgen receptor gene, which codes for a variable number 
of glutamine amino acids in the part of the receptor affecting 
gene transcription. A receptor with a short CAG sequence 
produces greater activity when androgens attach, and men 
with shorter CAG polymorphisms exhibit androgenic traits, 
such as preserved bone density (Zitzmann et al 2001) and 
prostate growth during testosterone treatment (Zitzmann et al 
2003). Indirect evidence of the importance of androgens in the 
development of prostate cancer is provided by case control 
study ﬁ  ndings of a shorter, more active CAG repeat sequence 
in the androgen receptor gene of patients with prostate cancer 
compared with controls (Hsing et al 2000, 2002).
More can be learned from a large, randomized, placebo-
controlled trial of ﬁ  nasteride treatment in 18,800 men aged 55 
or more. Finasteride is a 5α-reductase inhibitor which acts to 
prevent the metabolism of testosterone to dihydrotestosterone 
(DHT) – the most active androgen in the prostate. The trial 
showed a greater overall incidence of prostate cancer in the 
control group, but men treated with ﬁ  nasteride were more 
likely to have high grade tumors (Thompson et al 2003), 
suggesting that reduced androgen exposure of the prostate 
may delay the presentation of prostate cancer and/or promote 
advanced disease in some other way.
There have been case reports of development of pros-
tate cancer in patients during treatment with testosterone, 
including one case series of twenty patients (Gaylis et al 
2005). It is not known whether this reﬂ  ects an increase in 
incidence, as prostate cancer is very common and because 
the monitoring for cancer in patients treated with testoster-
one is greater. Randomized controlled trials of testosterone 
treatment have found a low incidence of prostate cancer and 
they do not provide evidence of a link between testosterone 
treatment and the development of prostate cancer (Rhoden 
and Morgentaler 2004). More large scale clinical trials of 
longer durations of testosterone replacement are required to 
conﬁ  rm that testosterone treatment does not cause prostate 
cancer. Overall, it is not known whether testosterone treat-
ment of aging males with hypogonadism increases the risk 
of prostate cancer, but monitoring for the condition is clearly 
vital. This should take the form of PSA blood test and rectal 
examination every three months for the ﬁ  rst year of treatment 
and yearly thereafter (Nieschlag et al 2005). Age adjusted 
PSA reference ranges should be used to identify men who 
require further assessment. The concept of PSA velocity is 
also important and refers to the rate of increase in PSA per 
year. Patients with abnormal rectal examination suggestive of 
prostate cancer, PSA above the age speciﬁ  c reference range or 
a PSA velocity greater than 0.75 ng/ml/yr should be referred 
to a urologist for consideration of prostate biopsy.
Testosterone and erectile 
dysfunction
Erectile dysfunction is a common ﬁ  nding in the aging male. A 
prevalence of over 70% was found in men older than 70 in a 
recent cross-sectional study (Ponholzer et al 2005). Treatment 
with phosphodiesterase-5 (PDE-5) inhibitors is proven to be 
effective for the majority of men but some do not respond 
(Shabsigh and Anastasiadis 2003). The condition is multi-
factorial, with contributions from emotional, vascular, neuro-
logical and pharmacological factors. The concept of erectile 
dysfunction as a vascular disease is particularly interesting in 
view of the evidence presented above, linking testosterone to 
atherosclerosis and describing its action as a vasodilator.
In a recent study of male workers, men with low tes-
tosterone levels had an increased chance of severe erectile 
dysfunction (Kratzik et al 2005), although such a link had not 
been found previously (Rhoden et al 2002). Certainly erectile 
dysfunction is considered part of the clinical syndrome of 
hypogonadism, and questions regarding erectile dysfunction 
form part of the clinical assessment of patients with hypogo-
nadism (Morley et al 2000; Moore et al 2004).
A previous meta-analysis has conﬁ  rmed that treatment of 
hypogonadal patients with testosterone improves erections 
compared to placebo (Jain et al 2000). A number of studies 
have investigated the effect of testosterone levels on erectile 
dysfunction in normal young men by inducing a hypogonadal 
state, for example by using a GnRH analogue, and then replac-
ing testosterone at varying doses to produce levels ranging 
from low-normal to high (Buena et al 1993; Hirshkowitz 
et al 1997). These studies have shown no signiﬁ  cant effects 
of testosterone on erectile function. These ﬁ  ndings contrast 
with a similar study conducted in healthy men aged 60–75, 
showing that free testosterone levels achieved with treat-
ment during the study correlate with overall sexual function, 
including morning erections, spontaneous erections and libido 
(Gray et al 2005). This suggests that the men in this older age 
group are particularly likely to suffer sexual symptoms if their 
testosterone is low. Furthermore, the severity of erectile dys-
function positively correlates with lower testosterone levels in 
men with type 2 diabetes (Kapoor, Clarke et al 2007).
There is increasing interest in the group of patients who 
fail to respond to treatment with PDE-5 inhibitors and have Clinical Interventions in Aging 2008:3(1) 36
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low serum testosterone levels. Evidence from placebo-
controlled trials in this group of men shows that testosterone 
treatment added to PDE-5 inhibitors improves erectile func-
tion compared to PDE-5 inhibitors alone (Aversa et al 2003; 
Shabsigh et al 2004).
It seems that adequate testosterone levels are an impor-
tant inﬂ  uence on sexual symptoms in the aging male and 
also inﬂ  uence the response of men to PDE-5 inhibitors, the 
ﬁ  rst line treatment for erectile dysfunction in men. Many 
would now suggest screening for testosterone deﬁ  ciency 
in all men presenting with erectile dysfunction (Gore and 
Rajfer 2004; Shabsigh 2005). This would seem appropriate 
because, in addition to beneﬁ  ts on sexual function, identiﬁ  -
cation and treatment of hypogonadal men with testosterone 
could improve other symptoms of hypogonadism and protect 
against other conditions such as osteoporosis.
Testosterone, mood, and cognition
Cognitive abilities differ between males and females and 
these differences are present from childhood. In broad terms, 
girls have stronger verbal skills than boys who tend to have 
stronger skills related to spatial ability (Linn and Petersen 
1985). It is thought that the actions of sex hormones have 
a role in these differences. Reviewing different cognitive 
strengths of male versus female humans is not within the 
scope of this article but the idea that cognition could be 
altered by testosterone deserves attention.
Cross-sectional studies have found a positive association 
between serum testosterone and some measures of cognitive 
ability in men (Barrett-Connor, Goodman-Gruen et al 1999; 
Yaffe et al 2002). Longitudinal studies have found that free 
testosterone levels correlate positively with future cognitive 
abilities and reduced rate of cognitive decline (Moffat et al 
2002) and that, compared with controls, testosterone levels 
are reduced in men with Alzheimer’s disease at least 10 years 
prior to diagnosis (Moffat et al 2004). Studies of the effects 
of induced androgen deﬁ  ciency in patients with prostate 
cancer have shown that profoundly lowering testosterone 
leads to worsening cognitive functions (Almeida et al 2004; 
Salminen et al 2004) and increased levels of serum amyloid 
(Gandy et al 2001; Almeida et al 2004), which is central 
to the pathogenesis of Alzheimer’s disease (Parihar and 
Hemnani 2004). Furthermore, testosterone reduces amyloid-
induced hippocampal neurotoxity in vitro (Pike 2001) as 
well as exhibiting other neuroprotective effects (Pouliot et al 
1996). The epidemiological and experimental data propose a 
potential role of testosterone in protecting cognitive function 
and preventing Alzheimer’s disease.
Studies of the effects on cognition of testosterone 
treatment in non-cognitively impaired eugonadal and hypo-
gonadal ageing males have shown varying results, with some 
showing beneﬁ  cial effects on spatial cognition (Janowsky 
et al 1994; Cherrier et al 2001), verbal memory (Cherrier 
et al 2001) and working memory (Janowsky et al 2000), 
and others showing no effects (Sih et al 1997; Kenny et al 
2002). Other trials have examined the effects of testosterone 
treatment in older men with Alzheimer’s disease or cogni-
tive decline. Results have been promising, with two studies 
showing beneﬁ  cial effects of testosterone treatment on spatial 
and verbal memory (Cherrier et al 2005b) and cognitive 
assessments including visual-spatial memory (Tan and Pu 
2003), and a recent randomized controlled trial compar-
ing placebo versus testosterone versus testosterone and an 
aromatase inhibitor suggesting that testosterone treatment 
improves spatial memory directly and verbal memory after 
conversion to estrogen (Cherrier et al 2005a). Not all stud-
ies have shown positive results (Kenny et al 2004; Lu et al 
2005), and variations could be due to the different measures 
of cognitive abilities that were used and the cognitive state of 
men at baseline. The data from clinical trials offers evidence 
that testosterone may be beneﬁ  cial for certain elements of 
cognitive function in the aging male with or without cogni-
tive decline. Larger studies are needed to conﬁ  rm and clarify 
these effects.
Mood disturbance and dysthymia are part of the clinical 
syndrome of hypogonadism. Epidemiological studies have 
found a positive association between testosterone levels and 
mood, and depressed aging males have lower testosterone 
levels than controls (Barrett-Connor, Von Muhlen et al 
1999). Furthermore, induction of a hypogonadal state during 
treatment of men for prostate cancer leads to an increase in 
depression scores (Almeida et al 2004). Trials of testos-
terone treatment effects on mood have varied in outcome. 
Data on the effects on men with depression are conﬂ  icting 
(Seidman et al 2001; Pope et al 2003) but there is evidence 
that testosterone treatment of older hypogonadal men does 
result in improvements in mood (Wang et al 1996) and that 
this may occur through changes in regional brain perfusion 
(Azad et al 2003).
Treating hypogonadism – general 
considerations
The aim of treatment for hypogonadism is to normalize 
serum testosterone levels and abolish symptoms or pathologi-
cal states that are due to low testosterone levels. The exact 
target testosterone level is a matter of debate, but current Clinical Interventions in Aging 2008:3(1) 37
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recommendations advocate levels in the mid-lower normal 
adult range (Nieschlag et al 2005). Truly physiological tes-
tosterone replacement would require replication of the diurnal 
rhythm of serum testosterone levels, but there is no current 
evidence that this is beneﬁ  cial (Nieschlag et al 2005).
At the present time, it is suggested that androgen replace-
ment should take the form of natural testosterone. Some of 
the effects of testosterone are mediated after conversion to 
estrogen or dihydrotestosterone by the enzymes aromatase 
and 5a-reductase enzymes respectively. Other effects occur 
independently of the traditional action of testosterone via 
the classical androgen receptor- for example, its action as a 
vasodilator via a cell membrane action as described previ-
ously. It is therefore important that the androgen used to treat 
hypogonadism is amenable to the action of these metaboliz-
ing enzymes and can also mediate the non-androgen receptor 
actions of testosterone. Use of natural testosterone ensures 
this and reduces the chance of non-testosterone mediated 
adverse effects. There are now a number of testosterone 
preparations which can meet these recommendations and the 
main factor in deciding between them is patient choice.
Regardless of the method of testosterone treatment 
chosen, patients will require regular monitoring during the 
ﬁ  rst year of treatment in order to monitor clinical response 
to testosterone, testosterone levels and adverse effects, 
including prostate cancer (see Table 2). It is recommended 
that patients should be reviewed at least every three months 
during this time. Once treatment has been established, less 
frequent review is appropriate but the care of the patient 
should be the responsibility of an appropriately trained 
specialist with sufﬁ  cient experience of managing patients 
treated with testosterone.
Testosterone preparations
Currently available testosterone preparations in common use 
include intramuscular injections, subcutaneous pellets, buc-
cal tablets, transdermal gels and patches (see Table 2). Oral 
testosterone is not widely used. Unmodiﬁ  ed testosterone taken 
orally is largely subject to ﬁ  rst-pass metabolism by the liver. 
Oral doses 100 fold greater than physiological testosterone pro-
duction can be given to achieve adequate serum levels. Methyl 
testosterone esters have been associated with hepatotoxicity. 
There has been some use of testosterone undecanoate, which 
is an esteriﬁ  ed derivative of testosterone that is absorbed via 
the lymphatic system and bypasses the liver. Unfortunately, 
it produces unpredictable testosterone levels and increases 
Table 2 The advantages and disadvantages of available testosterone preparations with advantages and disadvantages of each
Preparation Introduced  Advantages  Disadvantages
Subcutaneous pellet  1940s  Cheap  Infection around pellet
      Infrequent dosing  Extrusion of pellet
      Physiological levels  Requires doctor to insert
         Difﬁ  cult to reverse treatment 
Intramuscular injection  1950s  Cheap  Non-physiological levels
(Standard)       Fall in levels between injections
         which may cause symptoms
         Not usually self administered
Intramuscular injection  2000s  Infrequent dosing  Unable to reverse treatment at
(Long acting)     Physiological levels  short notice
         Given by nurse
         Cost
Transdermal patch  1990s  Physiological levels  Frequent skin irritation
      Convenient  May be unsightly
      Self administered  Cost
         Frequent dosing
Transdermal gel  2000s  Physiological levels  Skin irritation
      Convenient  Cost
      Self administered  Frequent dosing
Buccal tablets  2000s  Physiological levels  Presence on gum may irritate
      Convenient  Visibility
      Self administered  Cost
         Frequent dosing
Oral testosterone  1970s  Convenient  Non-physiological levels
(undecanoate)     Self administered  Short duration of action
        Multiple doses needed per dayClinical Interventions in Aging 2008:3(1) 38
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testosterone levels for only a short period after each oral 
dose (Schurmeyer et al 1983).
Intramuscular testosterone injections were ﬁ  rst used 
around ﬁ  fty years ago. Commercially available preparations 
contain testosterone esters in an oily vehicle. Esteriﬁ  cation is 
designed to retard the release of testosterone from the depot 
site into the blood because the half life of unmodiﬁ  ed testos-
terone would be very short. For many years intramuscular 
preparations were the most commonly used testosterone 
therapy and this is still the case in some centers. Pain can 
occur at injection sites, but the injections are generally well 
tolerated and free of major side effects. Until recently, the 
available intramuscular injections were designed for use at 
a frequency of between weekly and once every four weeks. 
These preparations are the cheapest mode of testosterone 
treatment available, but often cause supraphysiological 
testosterone levels in the days immediately following injec-
tion and/or low trough levels prior to the next injection 
during which time the symptoms of hypogonadism may 
return (Nieschlag et al 1976). More recently, a commercial 
preparation of testosterone undecanoate for intramuscular 
injection has become available. This has a much longer half 
life and produces testosterone levels in the physiological 
range throughout each treatment cycle (Schubert et al 2004). 
The usual dose frequency is once every three months. This 
is much more convenient for patients but does not allow 
prompt cessation of treatment if a contraindication to testos-
terone develops. The most common example of this would 
be prostate cancer and it has therefore been suggested that 
shorter acting testosterone preparations should preferably 
used for treating older patients (Nieschlag et al 2005). Similar 
considerations apply to the use of subcutaneous implants 
which take the form of cylindrical pellets injected under the 
skin of the abdominal wall and steadily release testosterone 
to provide physiological testosterone levels for up to six 
months. Problems also include pellet extrusion and infection 
(Handelsman et al 1997).
Transdermal preparations of testosterone utilize the 
fact that the skin readily absorbs steroid hormones. Initial 
transdermal preparations took the form of scrotal patches 
with testosterone loaded on to a membranous patch. 
Absorption from the scrotal skin was particularly good and 
physiological levels of testosterone with diurnal variation 
were reliably attained. The scrotal patches are now rarely 
used because they require regular shaving or clipping of 
scrotal hair and because they produce rather high levels of 
dihydrotestosterone compared to testosterone (Behre et al 
1999). Subsequently, non-scrotal patches were developed 
but the absorptive capacity of non-scrotal skin is much 
lower, so these patches contain additional chemicals which 
enhance absorption. The non-scrotal skin patches produce 
physiological testosterone levels without supraphysiologi-
cal dihydrotestosterone levels. Unfortunately, the patches 
produce a high rate of local skin reactions often leading to 
discontinuation (Parker and Armitage 1999). In the last few 
years, transdermal testosterone gel preparations have become 
available. These require daily application by patients and 
produce steady state physiological testosterone levels within 
a few days in most patients (Swerdloff et al 2000; Steidle et al 
2003). The advantages compared with testosterone patches 
include invisibility, reduced skin irritation and the ability 
to adjust dosage, but concerns about transfer to women and 
children on close skin contact necessitate showering after 
application or coverage with clothes.
Another recent development is the production of adhesive 
tablets which are applied twice daily to the buccal mucosa 
on the gum above the incisor teeth. The tablets gradually 
release testosterone into the systemic venous circulation 
and steady state physiological concentrations are achieved 
in most patients within two days (Ross et al 2004). Some 
patients do not like the feeling of the tablet in the mouth 
or ﬁ  nd that there is an abnormal taste in the mouth, but 
local adverse effects are usually mild and transient (Wang, 
Swerdloff et al 2004).
A full review of available testosterone preparations can 
be found elsewhere (Nieschlag et al 2004).
Testosterone treatment – adverse 
events, contraindications
A large number of side-effects have been attributed to 
testosterone. In our clinical experience, the incidence 
of significant adverse effects with treatment producing 
physiological testosterone levels is low, and many side 
effects attributed to testosterone are mainly relevant to 
supraphysiological replacement. Some adverse effects are 
speciﬁ  c to a given mode of delivery and have already been 
described. Potential adverse effects concerning the prostate 
have also been discussed and require appropriate monitoring 
of symptoms, PSA and digital rectal examination. Other 
tumors which may be androgen responsive include cancer 
of the breast and primary liver tumors, and these are both 
contraindications to testosterone treatment
Another effect that can limit treatment is polycythemia, 
which occurs due to various stimulatory effects of 
testosterone on erythropoiesis (Zitzmann and Nieschlag 
2004). Polycythemia is known to produce increased Clinical Interventions in Aging 2008:3(1) 39
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rates of cerebral ischemia and there have been reports of 
stroke during testosterone induced polycythaemia (Krauss 
et al 1991). It is necessary to monitor hematocrit during 
testosterone treatment, and hematocrit greater than 50% 
should prompt either a reduction of dose if testosterone levels 
are high or high-normal, or cessation of treatment if levels 
are low-normal. On the other hand, late onset hypogonadism 
frequently results in anemia which will then normalize during 
physiological testosterone replacement.
Sleep apnea is another frequently listed contraindication 
to testosterone treatment. There have been a few reports of 
the development, or worsening, of sleep apnea during tes-
tosterone therapy (Matsumoto et al 1985) but sleep apnea 
is actually associated with lower serum testosterone levels 
(Luboshitzky et al 2002). The reduction in fat mass during 
treatment with testosterone could potentially be beneﬁ  cial for 
sleep apnea, so many specialists will still consider patients 
for treatment with appropriate monitoring. It is wise to take a 
clinical history for sleep apnea during testosterone treatment 
in all men and perform sleep studies in those who develop 
symptoms.
Mental status changes including excess aggression are a 
well known phenomenon in the context of anabolic steroid 
abuse (Perry et al 1990). An increase in self-reported aggres-
sive behaviors have also been reported in one double blind 
placebo controlled trial of testosterone in young hypogonadal 
men (Finkelstein et al 1997), but this has not been conﬁ  rmed 
in other studies (Skakkebaek et al 1981; O’Connor et al 
2002). Aggression should therefore be monitored but in our 
experience is rarely a signiﬁ  cant problem during testosterone 
replacement producing physiological levels.
Overall, few patients have a compelling contraindication 
to testosterone treatment. The majority of men with late 
onset hypogonadism can be safely treated with testosterone 
but all will require monitoring of prostate parameters HDL 
cholesterol, hematocrit and psychological state. It is also 
wise to monitor symptoms of sleep apnea. Other speciﬁ  c 
concerns may be raised by the mode of delivery such as local 
side effects from transdermal testosterone.
Conclusion
Male hypogonadism becomes more common with increasing 
age and is currently an under-treated condition. The diagnosis 
of hypogonadism in the aging male requires a combination of 
symptoms and low serum testosterone levels. The currently 
available testosterone preparations can produce consistent 
physiological testosterone levels and provide for patient 
preference.
Some of the effects of testosterone treatment are well 
recognised and it seems clear that testosterone treatment for 
aging hypogonadal men can be expected to increase lean 
body mass, decrease visceral fat mass, increase bone mineral 
density and decrease total cholesterol. Beneﬁ  cial effects have 
been seen in many trials on other parameters such as glyce-
mic control in diabetes, erectile dysfunction, cardiovascular 
risk factors, angina, mood and cognition. These potentially 
important effects require conﬁ  rmation in larger clinical tri-
als. Indeed, it is apparent that longer duration randomized 
controlled trials of testosterone treatment in large numbers 
of men are needed to conﬁ  rm the effects of testosterone on 
many aspects of aging male health including cardiovascular 
health, psychiatric health, prostate cancer and functional 
capacity. In the absence of such studies, it is necessary to 
balance risk and beneﬁ  t on the best available data. At the 
present time the data supports the treatment of hypogonadal 
men with testosterone to normalize testosterone levels and 
improve symptoms. Most men with hypogonadism do not 
have a contraindication to treatment, but it is important to 
monitor for adverse consequences including prostate com-
plications and polycythemia.
Important future developments will include selective 
androgen receptor modulators (SARMs). These drugs will be 
able to produce isolated effects of testosterone at androgen 
receptors. They are likely to become useful clinical drugs, 
but their initial worth may lie in facilitating research into the 
relative importance of testosterone’s action at the androgen 
receptor compared to at other sites or after conversion to other 
hormones. Testosterone will remain the treatment of choice 
for late onset hypogonadism for some time to come.
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